S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
Log in

Jazz Pharmaceuticals Stock Forecast, Price & News

+0.29 (+0.17 %)
(As of 01/20/2021 12:00 AM ET)
Today's Range
Now: $167.29
50-Day Range
MA: $156.92
52-Week Range
Now: $167.29
Volume569,647 shs
Average Volume597,631 shs
Market Capitalization$9.32 billion
P/E Ratio52.77
Dividend YieldN/A
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia. The company also offers JZP-258, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for some narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and lurbinectedin, a product candidate under clinical investigation for the treatment of patients with relapsed small cell lung cancer. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc . The company was founded in 2003 and is headquartered in Dublin, Ireland.
Jazz Pharmaceuticals logo


Overall MarketRank

1.87 out of 5 stars

Medical Sector

99th out of 1,928 stocks

Pharmaceutical Preparations Industry

45th out of 774 stocks

Analyst Opinion: 2.4Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:JAZZ



Sales & Book Value

Annual Sales$2.16 billion
Cash Flow$22.79 per share
Book Value$54.99 per share


Net Income$523.37 million


Market Cap$9.32 billion
Next Earnings Date2/23/2021 (Estimated)
+0.29 (+0.17 %)
(As of 01/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive JAZZ News and Ratings via Email

Sign-up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Jazz Pharmaceuticals (NASDAQ:JAZZ) Frequently Asked Questions

How has Jazz Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Jazz Pharmaceuticals' stock was trading at $108.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, JAZZ stock has increased by 54.8% and is now trading at $167.29.
View which stocks have been most impacted by COVID-19

Is Jazz Pharmaceuticals a buy right now?

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 16 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Jazz Pharmaceuticals stock.
View analyst ratings for Jazz Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Jazz Pharmaceuticals?

Wall Street analysts have given Jazz Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Jazz Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Jazz Pharmaceuticals' CEO?

1,428 employees have rated Jazz Pharmaceuticals CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among Jazz Pharmaceuticals' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Jazz Pharmaceuticals' next earnings date?

Jazz Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Jazz Pharmaceuticals

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) released its quarterly earnings data on Monday, November, 2nd. The specialty pharmaceutical company reported $4.31 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $4.08 by $0.23. The specialty pharmaceutical company earned $600.90 million during the quarter, compared to the consensus estimate of $577.62 million. Jazz Pharmaceuticals had a return on equity of 20.16% and a net margin of 7.86%. The business's quarterly revenue was up 11.8% on a year-over-year basis. During the same period in the previous year, the company posted $4.10 earnings per share.
View Jazz Pharmaceuticals' earnings history

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals issued an update on its FY20 earnings guidance on Monday, November, 2nd. The company provided EPS guidance of $12.20-$13.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $12.48. The company issued revenue guidance of $2.32-$2.38 billion, compared to the consensus revenue estimate of $2.28 billion.

What price target have analysts set for JAZZ?

18 brokerages have issued 12-month target prices for Jazz Pharmaceuticals' stock. Their forecasts range from $113.00 to $233.00. On average, they expect Jazz Pharmaceuticals' stock price to reach $172.22 in the next year. This suggests a possible upside of 2.9% from the stock's current price.
View analysts' price targets for Jazz Pharmaceuticals
or view Wall Street analyst' top-rated stocks.

Who are some of Jazz Pharmaceuticals' key competitors?

What other stocks do shareholders of Jazz Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib).

Who are Jazz Pharmaceuticals' key executives?

Jazz Pharmaceuticals' management team includes the following people:
  • Mr. Bruce C. Cozadd, Co-Founder, Chairman & CEO (Age 56, Pay $2.33M)
  • Mr. Daniel N. Swisher Jr., Pres & COO (Age 57, Pay $1.24M)
  • Ms. Neena M. Patil J.D., Sr. VP & Gen. Counsel (Age 45, Pay $331.61k)
  • Dr. Robert Iannone M.D., Exec. VP of R&D (Age 53, Pay $771.48k)
  • Ms. Renée D. Galá, Exec. VP & CFO (Age 48)
  • Ms. Patricia Carr, VP of Fin. & Principal Accounting Officer (Age 49)
  • Dr. Finbar Larkin Ph.D., Sr. VP of Technical Operations (Age 62)
  • Dr. Katherine A. Littrell, VP of Investor Relations
  • Mr. George Eliades Ph.D., Sr. VP of Corp. Devel. & Chief Transformation Officer
  • Ms. Heidi Manna, Sr. VP & Chief HR Officer

What is Jazz Pharmaceuticals' stock symbol?

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

Who are Jazz Pharmaceuticals' major shareholders?

Jazz Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.39%), Wedge Capital Management L L P NC (0.32%), Denali Advisors LLC (0.03%), Bowling Portfolio Management LLC (0.02%), Ellis Investment Partners LLC (0.02%) and State of Alaska Department of Revenue (0.02%). Company insiders that own Jazz Pharmaceuticals stock include Bruce C Cozadd, Catherine A Sohn, Finbar Larkin, Kenneth W O'keefe, Matthew P Young, Michael Patrick Miller, Patricia Carr, Patrick G Enright, Paul L Berns, Paul Treacy, Seamus Mulligan and Suzanne Sawochka Hooper.
View institutional ownership trends for Jazz Pharmaceuticals

Which institutional investors are selling Jazz Pharmaceuticals stock?

JAZZ stock was sold by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC, Denali Advisors LLC, Ellis Investment Partners LLC, Bowling Portfolio Management LLC, Park Avenue Securities LLC, Busey Wealth Management, Boenning & Scattergood Inc., and State of Alaska Department of Revenue. Company insiders that have sold Jazz Pharmaceuticals company stock in the last year include Bruce C Cozadd, Finbar Larkin, Michael Patrick Miller, Patricia Carr, Patrick G Enright, and Paul L Berns.
View insider buying and selling activity for Jazz Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Jazz Pharmaceuticals stock?

JAZZ stock was purchased by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Pacer Advisors Inc., Prairiewood Capital LLC, Crossmark Global Holdings Inc., and Exchange Traded Concepts LLC.
View insider buying and selling activity for Jazz Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Jazz Pharmaceuticals' stock price today?

One share of JAZZ stock can currently be purchased for approximately $167.29.

How big of a company is Jazz Pharmaceuticals?

Jazz Pharmaceuticals has a market capitalization of $9.32 billion and generates $2.16 billion in revenue each year. The specialty pharmaceutical company earns $523.37 million in net income (profit) each year or $14.60 on an earnings per share basis. Jazz Pharmaceuticals employs 1,620 workers across the globe.

What is Jazz Pharmaceuticals' official website?

The official website for Jazz Pharmaceuticals is www.jazzpharma.com.

How can I contact Jazz Pharmaceuticals?

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at 011-353-1634-7800 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.